CClinicalTrials.gg
CompletedNCT05742828ALSUpdated May 6, 2023

Virtual Seating Coach on Power Wheelchairs of Persons With Amyotrophic Lateral Sclerosis (ALS)

An interventional study of Virtual Seating Coach in Amyotrophic Lateral Sclerosis, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 5 years 4 months after the study started (first participant enrolled Sep 2017, registered Feb 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A literature review was completed related to the topic of use of the Virtual Seating Coach (VSC) device with clients with Amyotrophic Lateral Sclerosis (ALS) with no results. The VSC components are FDA approved and Health Insurance Portability and Accountability Act (HIPPA) compliant, which have been used for many years by clinicians to achieve therapy goals of repositioning and best practice of utilizing power wheelchair seat functioning on a frequent basis. The VSC is typically not covered by insurance, but with clinical documentation, it has the potential for reimbursement. There is conflicting and vague information in the literature with regards to the prevalence/types of wounds and prevalence of pain in this population.

Read the detailed description

According to most literature, clients with ALS in general, get few pressure injuries. At this clinic, however, potentially due to the longer life expectancy of clients who choose tracheostomy with mechanical ventilation and a feeding tube, some clients do get pressure injuries. Also, many clients once they are sitting most of the day, whether in the wheelchair, recliner or bed, complain of discomfort and pain. Most clients will use or require a power wheelchair for mobility and positioning in the course of the disease process, and many will require it full time as symptoms progress. Generally, decreased sensation is not a symptom of ALS, but it is unknown why some people with ALS have pain and pressure injuries despite the intact sensation needed to cue repositioning.

It is best clinical practice to provide clients with ALS power wheelchairs that tilt, recline, and have leg elevation for maximal pressure management and to encourage repositioning to reduce the risk of skin breakdown/pressure injury as well as decrease pain. This study will study the effect of having an alerting/coaching system for training and reminders on performing pressure relief and repositioning for decreasing the number of pressure injuries as well as decreasing pain. The VSC also gives contextual cues to achieve a specific angle set-up by the clinician. Not only does the VSC provide alerts, but the client and clinician can observe and track the amount of time the chair is on and in what position.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Power wheelchairs
  • pressure injuries
  • pain
03

In context

Motor Neuron Disease

717 studies on the registry are indexed under Motor Neuron Disease; 137 are open to participants now.

This study's enrollment of 39 is above the median of 35 across 461 interventional studies indexed under Motor Neuron Disease.

Browse Motor Neuron Disease studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,320 studies on the registry; 199 are open to participants now.

Of its 323 completed or terminated interventional studies of FDA-regulated products, 243 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Treatment group:

  • Inclusion will be diagnosis of amyotrophic lateral sclerosis (ALS)
  • Current clinic client at The Carolinas Neuromuscular ALS/MDA Center's Multidisciplinary ALS clinic
  • Currently using a Permobil power wheelchair with power seating with R-Net electronics that accepts the VSC
  • Has a Permobil Corpus 3G (6 months old or newer) or who order a new Permobil power wheelchair.
  • New Permobil chairs which are not obtained through this clinic will also be able to enter the study, such as chairs from other regions or from the Veteran's Administration.

Comparison group:

  • Inclusion will be diagnosis of ALS
  • Current clinic client at The Carolinas Neuromuscular ALS/Muscular Dystrophy Association (MDA) Center's multidisciplinary ALS clinic
  • Currently using a power wheelchair with power seating.
  • New chairs which are not obtained through this clinic will also be able to enter the study, such as chairs from other regions or from the Veteran's Administration.

Exclusion Criteria:

Treatment group:

  • Another diagnosis besides ALS
  • Does not have a Smart phone or tablet
  • Frontotemporal Dementia as noted by MD/SLP/SW (Medical Doctor/Speech Language Pathologist/Social Worker) in medical records
  • Inability/unwillingness to control wheelchair power features (client)
  • Unwillingness to be monitored by study staff and alerted by VSC over time
  • Uses other mobility devices indoors (scooter, basic power wheelchair) more than or in addition to Permobil PWC

Comparison group:

  • Another diagnosis besides ALS
  • Frontotemporal Dementia as noted by MD/SLP/SW in medical records
  • Inability/unwillingness to control wheelchair power features (client)
  • Unwillingness to be monitored by study staff
  • Uses other mobility devices indoors (scooter, basic power wheelchair) more than or in addition to power wheelchair
  • Further exclusions may be added in future protocol versions
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Active comparator
    Virtual Seating Coach

    The Virtual Seating Coach is a context-aware reminding system that when set up by a clinician, directly benefits a user by reminding him or her to change position with the chair's power seating function.. Regular position changes increase independent function, reduce the risk of pressure ulcers, manage pain, and reduce swelling.

    Behavioral: Virtual Seating Coach

  • No intervention
    Non Virtual Seating Coach

    power wheelchairs that tilt, recline, and have leg elevation for maximal pressure management and to encourage repositioning to reduce the risk of skin breakdown/pressure injury as well as decrease pain.

Interventions

  • BehavioralVirtual Seating Coach

    Power wheelchair intervention

06

What researchers measure

Primary outcomes

  1. Change in seat function utilization with use of the Virtual Seating Coach (VSC)

    tracked through the Virtual Seating Coach app and Permobil data collection

    Time frame: Year 3

  2. Change in number of Complications

    Pressure and pain questions measured using a Likert Scale - A type of psychometric response scale in which responders specify their level of agreement to a statement typically in five points: (1) Strongly disagree; (2) Disagree; (3) Neither agree nor disagree; (4) Agree; (5) Strongly agree.

    Time frame: Year 3

Secondary outcomes

  1. Change in Utilization of VSC

    If limitations are addressed (respiratory, cushion, comfort, control) does utilization increase? - evaluated with surveys and phone calls

    Time frame: Year 3

07

Study locations

1 site
  • Atrium Health - Neurosciences Institute
    Charlotte, North Carolina 28207, United States
08

References and documents

Study documents

  • Informed consent form · Dec 28, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05742828
Lead sponsor
Wake Forest University Health Sciences
Collaborators
Permobil, Inc.
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Sep 20, 2017
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Last update
May 6, 2023

Study contacts

Amber Ward, MS, OTR/L
principal investigator · Carolinas Neuromuscular ALS/MDA Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion